Literature DB >> 12694251

Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia.

Gordon W Dewald1, Stephanie R Brockman, Sarah F Paternoster, Nancy D Bone, Judith R O'Fallon, Cristine Allmer, Charles D James, Diane F Jelinek, Renee C Tschumper, Curtis A Hanson, Rajiv K Pruthi, Thomas E Witzig, Timothy G Call, Neil E Kay.   

Abstract

Fluorescence in situ hybridization (FISH) was used to detect 6q-, 11q-, +12, 13q-, 17p- and translocations involving 14q32 in interphase nuclei from blood and/or bone marrow from 113 patients with B-cell chronic lymphocytic leukaemia (B-CLL). A total of 87 patients (77%) had a FISH anomaly: 13q- x 1 was most frequent (64%) followed by 13q- x 2 (28%), +12 (25%), 11q- (15%), 17p- (8%) and 6q- (0%). FISH results for blood and bone marrow cells in 38 patients were similar. Purified CD5+/CD19+ cells from blood were studied in eight patients and results indicate that in some patients not all B cells have FISH anomalies. We used a defined set of hierarchical FISH risk categories to compare FISH results by stable versus progressive disease, age, sex, Rai stage, CD38+ expression and IgVH mutational status. Significant differences in FISH risk distributions were associated with Rai stage, disease status and CD38+, but not by age, sex or IgVH mutational status. To look for baseline factors associated with high-risk disease, multivariate analysis of age, sex, Rai stage, CD38+ and disease status versus FISH risk category was performed. Importantly, only CD38+ was significantly associated with high-risk FISH categories (+12, 11q- and 17p-) after adjustment for the effects of other variables.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694251     DOI: 10.1046/j.1365-2141.2003.04265.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  69 in total

1.  Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Authors:  Tait D Shanafelt; Neil E Kay; Kari G Rabe; David J Inwards; Clive S Zent; Jose F Leis; Susan M Schwager; Carrie A Thompson; Deborah A Bowen; Thomas E Witzig; Susan L Slager; Timothy G Call
Journal:  Cancer       Date:  2011-08-26       Impact factor: 6.860

2.  Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.

Authors:  David M Lucas; Amy S Ruppert; Gerard Lozanski; Gordon W Dewald; Arletta Lozanski; Rainer Claus; Christoph Plass; Ian W Flinn; Donna S Neuberg; Elisabeth M Paietta; John M Bennett; Diane F Jelinek; John G Gribben; Mohamad A Hussein; Frederick R Appelbaum; Richard A Larson; Dennis F Moore; Martin S Tallman; John C Byrd; Michael R Grever
Journal:  Leuk Lymphoma       Date:  2015-03-30

Review 3.  Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.

Authors:  Neil E Kay; Susan M Geyer; Timothy G Call; Tait D Shanafelt; Clive S Zent; Diane F Jelinek; Renee Tschumper; Nancy D Bone; Gordon W Dewald; Thomas S Lin; Nyla A Heerema; Lisa Smith; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

5.  Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Tait D Shanafelt; Cristina Ivan; Masayoshi Shimizu; Kari G Rabe; Nazila Nouraee; Mariko Ikuo; Asish K Ghosh; Susan Lerner; Laura Z Rassenti; Lianchun Xiao; Jianhua Hu; James M Reuben; Steliana Calin; M James You; John T Manning; William G Wierda; Zeev Estrov; Susan O'Brien; Thomas J Kipps; Michael J Keating; Neil E Kay; George A Calin
Journal:  Blood       Date:  2013-07-02       Impact factor: 22.113

6.  Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Matthew T Drake; Matthew J Maurer; Cristine Allmer; Kari G Rabe; Susan L Slager; George J Weiner; Timothy G Call; Brian K Link; Clive S Zent; Neil E Kay; Curtis A Hanson; Thomas E Witzig; James R Cerhan
Journal:  Blood       Date:  2010-11-03       Impact factor: 22.113

7.  Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Michael J Conte; Deborah A Bowen; Gregory A Wiseman; Kari G Rabe; Susan L Slager; Susan M Schwager; Timothy G Call; David S Viswanatha; Clive S Zent
Journal:  Leuk Lymphoma       Date:  2014-02-17

8.  Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.

Authors:  Nisar A Baig; Ronald P Taylor; Margaret A Lindorfer; Amy K Church; Betsy R LaPlant; Adam M Pettinger; Tait D Shanafelt; Grzegorz S Nowakowski; Clive S Zent
Journal:  J Immunol       Date:  2014-01-15       Impact factor: 5.422

9.  Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia.

Authors:  Shanique Palmer; Curtis A Hanson; Clive S Zent; Luis F Porrata; Betsy Laplant; Susan M Geyer; Svetomir N Markovic; Timothy G Call; Deborah A Bowen; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2008-04-01       Impact factor: 6.998

Review 10.  Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia.

Authors:  Clive S Zent; Neil E Kay
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.